Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers
Journal Impact Factor 1.25*
Submit manuscript at https://www.editorialmanager.com/biomedicaljournals/ or send as an e-mail attachment to the Editorial Office at [email protected]
ICV Value: 64.66
Journal of Leukemia is a peer reviewed medical journal that includes a wide range of fields in Leukemia, Multiple Myeloma, Acute Lymphoblastic Leukemia, Acute Myleoid Leukemia, Chronic Lymphocytic Leukemia, Chronic Myleloid Leukemia, Hairy Cell Leukemia, Pediatric Leukemia, Leukemia drugs, Stem Cell Transplant, Plasma cell Leukemia, Mast cell Leukemia, Lymphoma Cancer, Lymphoma Symptoms, Spleen cancer, Acute Myelomonocytic Leukemia, Aleukemic Leukemia , Lymphosarcoma, Megakaryocytic Leukemia, Feline Leukemia complex, Epidemiologic studies and other Hematologic malignancies and creates a platform for the authors to make their contribution towards the journal and the editorial office promises peer process for the submitted manuscripts to ensure quality.
Leukemia is one of the best open access journals that aims to publish the most complete and reliable source of information on discoveries and current developments in the mode of Original articles, Review articles, Case reports, Short communications, etc. in the field and provides free online access to the researchers worldwide.
This scholarly open access journal is using Editorial Manager System for online manuscript submission, review and the progress of the article. Editorial board members of Journal of Leukemia or outside experts review manuscripts; at least two independent reviewer’s approval followed by the editor is required for the acceptance of any citable manuscript.
Leukemia is a cancer of the blood cells. Leukemia begins in a cell in the bone marrow. The cell undergoes a change and becomes a type of leukemia cell. Once the marrow cell undergoes a leukemic change, the leukemia cells may grow and survive better than normal cells. Over time, the leukemia cells crowd out or suppress the development of normal cells. The rate at which leukemia progresses and how the cells replace the normal blood and marrow cells are different with each type of leukemia.
It is the most common type of blood cancer and affects 10 times as many adults as children. Most people diagnosed with leukemia are over 50 years old.
Acute lymphocytic leukemia (ALL), also called acute lymphoblastic leukemia, is a cancer that starts from the early version of white blood cells called lymphocytes in the bone marrow (the soft inner part of the bones, where new blood cells are made). The term “acute” means that the leukemia can progress quickly, and if not treated, would probably be fatal within a few months. Lymphocytic means it develops from early (immature) forms of lymphocytes, a type of white blood cell. Acute leukemia requires aggressive, timely treatment.
Chronic myeloid leukemia (CML), also known as chronic myelogenous leukemia, is a type of cancer that starts in certain blood-forming cells of the bone marrow. In CML, a genetic change takes place in an early (immature) version of myeloid cells - the cells that make red blood cells, platelets, and most types of white blood cells (except lymphocytes). This change forms an abnormal gene called BCR-ABL, which turns the cell into a CML cell. The leukemia cells grow and divide, building up in the bone marrow and spilling over into the blood. In time, the cells can also settle in other parts of the body, including the spleen. CML is a fairly slow growing leukemia, but it can also change into a fast-growing acute leukemia that is hard to treat.
Pediatric Leukemia is also called as Juvenile Leukemia and childhood leukemia. Accounts for less than 1% of childhood leukemias Approx. 25-50 children are diagnosed each year in the US Children are usually diagnosed before 2 years old More common in boys than girls Symptoms can take months to develop Usually no symptoms are seen in the early stages Once diagnosed progressive deterioration occurs.
This Leukemia is the most commonly diagnosed cancer in children, accounting for about 30% of all cases. Approximately 1 in 2,000 children will develop it before the age of 15 years.
Plasma cell leukemia (PCL) is a rare and aggressive plasma cell dyscrasia. Patients with PCL have a very poor prognosis with median survival measured in months. PCL can present de novo or following a prodrome of plasma cell myeloma. Patients with PCL tend to present with aggressive clinical features, such as extramedullary disease, bone marrow failure. The treatment of PCL has primarily been palliative, with only a small minority of patients achieving a durable remission.
Mast cell leukemia (MCL) is a very rare form of aggressive systemic mastocytosis accounting for < 1% of all mastocytosis. It may appear de novo or secondary to previous mastocytosis and shares more clinicopathologic aspects with systemic mastocytosis than with acute myeloid leukemia. Symptoms of mast cell activation-involvement of the liver, spleen, peritoneum, bones, and marrow-are frequent.The common phenotypic features of pathologic mast cells encountered in most forms of mastocytosis are unreliable in MCL.
The most common symptom of lymphoma is a painless swelling in a lymph node, usually in the armpit, groin or neck. This is caused by the damaged lymphocytes collecting in that node. The swelling may also ache. Fever, Chills, Unexplained weight loss, These symptoms are nonspecific. This means that they could be caused by any number of conditions unrelated to cancer. For instance, they could be signs of the flu or other viral infection, but in those cases, they would not last very long. In lymphoma, the symptoms persist over time and cannot be explained by an infection or another disease.
Acute Myelomonocytic Leukemia one of the more common types of acute myelogenous leukemia, characterized by both malignant monocytes and myeloblasts; it usually affects middle aged to older adults, although it affects people of all ages. AML sometimes is caused by chemotherapy or radiation therapy given to treat another cancer.
In AML, immature leukemia cells rapidly accumulate in the bone marrow, destroying and replacing cells that produce normal blood cells. The leukemia cells are released into the bloodstream and are transported to other organs, where they continue to grow and divide. They can form small masses (chloromas) in or just under the skin or gums or in the eyes. There are several subtypes of AML, which are identified based on characteristics of the leukemia cells.
Leukemia is a serious disease, a cancer of blood or bone marrow. It is a cancer of white blood cells (WBCs). Abnormal production of leukocytes or white blood cells in the bone marrow leads to leukemia, resulting in several health complications. Aleukemic Leukemia is a leukemia in which the leukocyte count is normal or below normal.
In aleukemic leukemia, increased number of white blood cells is not detected in a blood test. It is a rare type of leukemia. This type of leukemia can also be lymphocytic, monocytic, or myelogenous. It can be seen in patients diagnosed with acute/chronic lymphocytic/meylogenous leukemia and also in prolymphocytic leukemia, and myelodysplastic syndrome.
Acute megakaryocytic leukemia (AMeL) is a rare form of acute myeloid leukemia (AML). Even if it is a well-known entity, it could be frequently misdiagnosed as acute myelosclerosis. The disease is rare and, due to difficulty in diagnosis, its exact incidence is not known. Reasonably, it may account for approximately 1-2% of all de novo acute myeloid leukemias (AML) in the adult population, but the incidence in the pediatric age group is higher, partly due to an association with Down syndrome. The incidence of this form of AML shows a high variability according to the different reports, that it ranges from 8 to 15% of all acute leukemias. Clinical experience with this rare leukemia remains limited.
Feline leukemia is a cancerous disease caused by feline leukemia virus (FeLV). Feline leukemia is a disease that only affects cats -- it cannot be transmitted to people, dogs, or other animals. FeLV is passed from one cat to another through saliva, blood, and to some extent, urine and feces. The virus does not live long outside the cat’s body -- probably just a few hours. FeLV is a type of virus called a retrovirus.
Only about 3% of cats in single-cat households have the virus, but for cats that spend time outdoors, the rate is much higher. Still, the prevalence of FeLV has decreased over the last 25 years because of vaccines and reliable tests.
OMICS International through its Open Access Initiative is committed to make genuine and reliable contributions to the scientific community. OMICS International hosts over 700 leading-edge peer reviewed Open Access Journals and organizes over 1000 International Conferences annually all over the world. OMICS International journals have over 10 million readers and the fame and success of the same can be attributed to the strong editorial board which contains over 50000 eminent personalities that ensure a rapid, quality and quick review process. OMICS International signed an agreement with more than 1000 International Societies to make healthcare information Open Access. OMICS International Conferences make the perfect platform for global networking as it brings together renowned speakers and scientists across the globe to a most exciting and memorable scientific event filled with much enlightening interactive sessions, world class exhibitions and poster presentations.
Journal of Leukemia is supporting the 5th World Conference on Cancer Therapy during september 28-30, 2015 Atlanta, USA with the theme of Exploring the Possibilities towards cancer treatment.
*2017 Journal Impact Factor was established by dividing the number of articles published in 2015 and 2016 with the number of times they are cited in 2017 based on Google Scholar Citation Index database. If 'X' is the total number of articles published in 2015 and 2016, and 'Y' is the number of times these articles were cited in indexed journals during 2017 then, journal impact factor = Y/X